Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry, has announced that its medical aesthetics subsidiary’s polylactic acid facial filler, AestheFill, has received marketing approval in China. The product is slated to become available in mainland China in the first half of 2024.
AestheFill, a medical aesthetics regeneration injection originally developed by South Korea-based REGEN Biotech Inc., is formulated with PDLLA microspheres and sodium carboxymethyl cellulose. Notably, the injection initially received regulatory approval in South Korea back in 2014.- Flcube.com
